Prof. Amnon Peled appointed to Silexion Therapeutics Corp's Board of Directors for cancer therapies

From GlobeNewswire: 2024-12-10 08:30:00

Prof. Amnon Peled has been appointed as an independent director to the Board of Directors at Silexion Therapeutics Corp. His expertise in cancer biology and therapeutic development will be instrumental in advancing the company’s RNAi-based therapies for challenging cancers driven by KRAS mutations. Prof. Peled’s appointment ensures compliance with Nasdaq listing requirements and reinforces Silexion’s commitment to scientific excellence in developing innovative cancer treatments. With over 28 years of experience in stem cell biology and immunology, Prof. Peled’s contributions to biotechnology have led to multiple FDA approvals and groundbreaking research collaborations with leading Israeli biotech companies.

Silexion Therapeutics Corp, a clinical-stage biotech company, has appointed Prof. Amnon Peled to its Board of Directors to advance its RNAi-based therapies for KRAS-driven cancers. Prof. Peled’s expertise in stem cell biology and cancer therapeutics aligns with Silexion’s mission to develop innovative treatments for difficult-to-treat cancers. His appointment ensures compliance with Nasdaq listing requirements and reinforces the company’s commitment to scientific and strategic excellence. Prof. Peled’s extensive experience in clinical development and regulatory pathways will contribute to Silexion’s goal of delivering impactful solutions for patients facing challenging cancers, solidifying the company’s position in the oncology market.



Read more at GlobeNewswire: Silexion Therapeutics Appoints Renowned Cancer Therapeutics